| Dear Subscriber, |
| Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories. To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
| Alcohol / Addiction / Illegal Drugs News | |
| CBT Helps Depressive Symptoms For Patients In Residential Substance Abuse Treatment Programs CBT (cognitive behavioral therapy) appears to help patients in drug and alcohol abuse treatment programs with symptoms of depression, researchers from the RAND Corporation, Santa Monica, California reported in Archives of General Psychiatry today. | 06 June 2011 |
| Allergy News | |
| Sunovion Announces FDA Acceptance Of New Drug Application For Ciclesonide HFA Nasal Aerosol Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation has been accepted by the U. | 06 June 2011 |
| Alzheimer's / Dementia News | |
| Weight Loss After Gastric Bypass Surgery Reduces Expression Of Alzheimer's Genes Obesity is a risk factor for Alzheimer's disease, but weight loss due to bariatric surgery may reduce the risk of this common dementia, a new study suggests. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Mild cognitive impairment may be linked to functional impairment among older patients The majority of older individuals with mild cognitive impairment also have problems with at least one type of function, researchers from the New York State Psychiatric Institute reported in Archives of General Psychiatry. | 06 June 2011 |
| Anxiety / Stress News | |
| Adult Partner Violence Linked To Childhood Bullying Males who bullied other children during their childhood are much more likely to be violent towards their intimates partners later on in life, researchers from the Harvard School of Public Health, Boston, reported in Archives of Pediatrics & Adolescent Medicine today. | 06 June 2011 |
| Arthritis / Rheumatology News | |
| Joint Replacement Surgery Riskier At Hospitals With Low Surgical Volume Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure. The complications following joint replacement surgery at low-volume sites may be reduced by modifying systems and procedures used before and after surgery according to the findings published today in Arthritis & Rheumatism, a peer-reviewed journal of the American College of Rheumatology (ACR). | 06 June 2011 |
| Autism News | |
| As People Age Their Moral Responses Change Moral responses change as people age says a new study from the University of Chicago.Both preschool children and adults distinguish between damage done either intentionally or accidently when assessing whether a perpetrator has done something wrong, said study author Jean Decety. | 06 June 2011 |
| Biology / Biochemistry News | |
| Finding Source Of E. Coli Outbreak In Germany - Why Has It Taken So Long? Dr. Mark Fielder, from Kingston University, London, has been keeping a close watch on how the European E. Coli outbreak has developed. Below, he answers some key question about the situation. | 06 June 2011 |
| Blood / Hematology News | |
| Survival Niche For Cancer Cells Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors. | 06 June 2011 |
| ARIAD Announces Initial Clinical Data On Ponatinib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML). In addition to being an investigational pan-BCR-ABL inhibitor for use in chronic myeloid leukemia (CML), ponatinib selectively and potently inhibits certain other tyrosine kinases, including a specific mutation of FLT3 called the internal tandem duplication (ITD). | 06 June 2011 |
| ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL). | 06 June 2011 |
| Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit For Myelofibrosis Patients In Two Phase III Studies At ASCO Annual Meeting Incyte Corporation (Nasdaq:INCY) announced today results from the global, pivotal Phase III clinical program of ruxolitinib (INCB18424 or INC424) in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. | 06 June 2011 |
| Bones / Orthopedics News | |
| Metastatic Soft-Tissue Or Bone Sarcomas, Oral Ridaforolimus Improved Progression-Free Survival The SUCCEED trial using oral ridaforolimus met its primary endpoint of progression-free survival in patients with metastatic soft-tissue or bone sarcomas who had responded well to chemotherapy, Merck announced at the American Society of Clinical Oncology Annual Meeting in Chicago today. | 06 June 2011 |
| Low Vitamin D Levels Are Related To Decreased Response To Osteoporosis Medicine Women with low bone density are seven times more likely to benefit from a bisphosphonate drug when their vitamin D blood levels are above recent recommendations from the Institute of Medicine (IOM) as adequate for bone health. | 06 June 2011 |
| Yearly Zoledronic Acid At Lower-than-Standard Doses Increases Bone Density A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. | 06 June 2011 |
| Athletic Girls More Likely To Have Impaired Bone Structure If Menstrual Cycle Stops Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. | 06 June 2011 |
| Stem Cell Treatment May Become Option To Treat Nonhealing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. | 06 June 2011 |
| Alpharadin Significantly Improves Overall Survival In Phase III In Patients With Castration-Resistant Prostate Cancer That Has Spread To The Bone Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival. | 06 June 2011 |
| Muscle Development: A Dance Of Cellular Skeletons Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell's territory, eventually forcing the cells to combine. | 06 June 2011 |
| Breast Cancer News | |
| Study Evaluating SIR-Spheres(R) Microspheres In Patients With Metastatic Breast Cancer Presented At The 2011 ASCO Annual Meeting Sirtex, a leading developer and manufacturer of targeted, innovative liver cancer therapies, today announced the results of a five-year study evaluating the tolerability, efficacy and survival rates of Selective Internal Radiation Therapy (SIRT), also known as radioembolization, using SIR-Spheres® microspheres in patients with liver metastases from breast cancer that are refractory to chemotherapy. | 06 June 2011 |
| Medifocus Inc. Announces Institutional Review Board (IRB) Approval For Second USA Site For Its Phase III Pivotal Breast Cancer Treatment Study Medifocus Inc. (OTC:MDFZF.PK) and (TSXV:MFS) is pleased to announce that the Western Institutional Review Board (WIRB) has granted IRB approval to the Comprehensive Breast Center of Coral Springs Florida, a division of 21st Century Oncology to conduct Medifocus' Pivotal Phase III Breast Cancer Treatment Study, under the supervision of Dr. | 06 June 2011 |
| Practice-Changing Cancer Trial Shows Additional Radiation Decreases Cancer Recurrence, Canada A Canadian-led clinical trial has found that additional radiation treatment improves disease-free survival in women with early breast cancer and reduces the risk of cancer recurrence, a finding that could change the standard treatment for this group of patients. | 06 June 2011 |
| Landmark Breast Cancer Prevention Trial Finds Exemestane Significantly Reduces Risk Of Breast Cancer, Canada A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo. | 06 June 2011 |
| Flaxseed No Cure For Hot Flashes During Breast Cancer Or Menopause Flaxseed provides no benefit in easing hot flashes among breast cancer patients and postmenopausal women, according to a Mayo Clinic and North Central Cancer Treatment Group (NCCTG) study. The randomized, placebo-controlled study was conducted on 188 women between October and December 2009 and found no statistically significant difference in mean hot flash scores between women taking flaxseed and those taking a placebo. | 06 June 2011 |
| Hormone Test Predicts Ovarian Function After Chemotherapy For Breast Cancer A test that shows how many eggs a woman has in her ovaries may help young women with breast cancer know what their reproductive function will be after chemotherapy, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Cancer / Oncology News | |
| Metastatic Soft-Tissue Or Bone Sarcomas, Oral Ridaforolimus Improved Progression-Free Survival The SUCCEED trial using oral ridaforolimus met its primary endpoint of progression-free survival in patients with metastatic soft-tissue or bone sarcomas who had responded well to chemotherapy, Merck announced at the American Society of Clinical Oncology Annual Meeting in Chicago today. | 06 June 2011 |
| Novartis' Gleevec Cancer "Magic Bullet" Extends Life In GIST Patients Stomach cancer and gastronintestinal stromal tumors (GIST) can be an expensive disease to treat, but for approximately $5,000 a month Novartis AG's cancer pill Gleevec (imatinib) seems to extend the lives of patients with this type of gastrointestinal cancer over the long-term when taking the drug for three years after surgery. | 06 June 2011 |
| Supplement Found To Improve Quality Of Life For Female Cancer Survivors A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center. | 06 June 2011 |
| Pre-Clinical Studies Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes. | 06 June 2011 |
| ZALTRAP™ (Aflibercept) Significantly Improved Survival In Previously Treated Metastatic Colorectal Cancer Patients Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011. | 06 June 2011 |
| Screenings Appear Not To Reduce Risk Of Ovarian Cancer Death A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems. | 06 June 2011 |
| Exelixis' Cabozantinib Demonstrates Broad Clinical Activity In Multiple Tumor Types Exelixis, Inc. (NASDAQ:EXEL) today reported updated interim data from an ongoing phase 2 adaptive randomized discontinuation trial (RDT) of cabozantinib in patients with advanced solid tumors. | 06 June 2011 |
| ImmunoGen, Inc. Announces Positive Clinical Data Presented On IMGN901 In The Treatment Of Multiple Myeloma ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation (abstract #8013) at the ASCO 2011 Annual Meeting in Chicago. | 06 June 2011 |
| Ipsen Announces Discontinuation Of The Development Of Irosustat In Monotherapy Ipsen (Paris:IPN) (Euronext: IPN - ADR: IPSEY) today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decision is based on the futility analysis from the proof-of-concept trial phase II clinical study carried out in Europe in monotherapy in endometrial cancer, and on the phase I/II clinical study results obtained in metastatic prostate and breast cancers. | 06 June 2011 |
| Survival Niche For Cancer Cells Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors. | 06 June 2011 |
| Clinical Trial At The Cancer Institute Of New Jersey Studies Combination Of ALS And Kidney Cancer Drugs For Melanoma Use Could a drug that is now used to treat a nerve cell condition and another prescribed to treat kidney cancer be combined to combat the deadliest form of skin cancer? That is the focus of research now underway at The Cancer Institute of New Jersey (CINJ), which aims to determine safe dosing levels for the drugs known as riluzole and sorafenib when used together in the treatment of patients with melanoma. | 06 June 2011 |
| Symphogen Presents Results From The First Clinical Trial With Sym004 At ASCO Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004. Based on the data, the poster authors concluded that Sym004 is well tolerated, and shows preliminary signs of clinical effect. | 06 June 2011 |
| Silence Therapeutics' Atu027 Demonstrates Promising Antitumor Activity In Phase I Study Presented At ASCO Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces positive updated data from its ongoing Phase I study of Atu027, one of the most clinically advanced RNAi therapeutics in the area of oncology, in patients with advanced solid tumors. | 06 June 2011 |
| Landmark UK-Led Trial Shows Avastin(R) (Bevacizumab) Can Prolong Life In Women With Advanced Ovarian Cancer Data presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago show, for the first time, that Avastin (bevacizumab) improves overall survival (OS) in women with advanced ovarian cancer2,3 - the deadliest gynaecological cancer in the UK1 - offering hope of a treatment breakthrough for thousands of women diagnosed with the disease each year. | 06 June 2011 |
| NewYork-Presbyterian/Weill Cornell Research Presented At American Society Of Clinical Oncologists Meeting Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The meeting takes place June 3-7, at McCormick Place, Chicago. | 06 June 2011 |
| Advanced Skin Cancer Hope With Vemurafenib And Ipilimumab Patients with advanced melanoma may live longer with Ipilimumab, and have a better likelihood of surviving longer on Vemurafenib than chemotherapy, scientists revealed in the Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Semuloparin Thwarts Venous Thromboembolism In Patients Starting Chemotherapy Semuloparin significantly decreases the risk of venous thromboembolism (VTE) by 64% compared to placebo in cancer patients initiating a chemotherapy regimen, according to results of the phase III SAVE-ONCO study reported at the 2011 American Society of Clinical Oncology (ASCO) meeting. | 06 June 2011 |
| ARIAD Announces Initial Clinical Data On Ponatinib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML). In addition to being an investigational pan-BCR-ABL inhibitor for use in chronic myeloid leukemia (CML), ponatinib selectively and potently inhibits certain other tyrosine kinases, including a specific mutation of FLT3 called the internal tandem duplication (ITD). | 06 June 2011 |
| Study Evaluating SIR-Spheres(R) Microspheres In Patients With Metastatic Breast Cancer Presented At The 2011 ASCO Annual Meeting Sirtex, a leading developer and manufacturer of targeted, innovative liver cancer therapies, today announced the results of a five-year study evaluating the tolerability, efficacy and survival rates of Selective Internal Radiation Therapy (SIRT), also known as radioembolization, using SIR-Spheres® microspheres in patients with liver metastases from breast cancer that are refractory to chemotherapy. | 06 June 2011 |
| BSD Medical Announces Clinical Role Of Hyperthermia Was The Focus At European Society For Hyperthermic Oncology Meeting BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the clinical role of hyperthermia was the focus at the annual European Society for Hyperthermic Oncology (ESHO) Meeting, which was held in Aarhus, Denmark, May 26-28, 2011. | 06 June 2011 |
| Medifocus Inc. Announces Institutional Review Board (IRB) Approval For Second USA Site For Its Phase III Pivotal Breast Cancer Treatment Study Medifocus Inc. (OTC:MDFZF.PK) and (TSXV:MFS) is pleased to announce that the Western Institutional Review Board (WIRB) has granted IRB approval to the Comprehensive Breast Center of Coral Springs Florida, a division of 21st Century Oncology to conduct Medifocus' Pivotal Phase III Breast Cancer Treatment Study, under the supervision of Dr. | 06 June 2011 |
| ASCO 2011: New Analysis Further Reinforces Erbitux Benefits For Patients With Metastatic Bowel Cancer At the start of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Merck Serono, a division of Merck KGaA, Darmstadt, Germany, presented a retrospective analysis of the CRYSTAL and OPUS trials which demonstrated that, by treating a specific population of metastatic bowel cancer patients (KRAS wild-type) with Erbitux® (cetuximab) in combination with standard chemotherapy1: - Overall survival was significantly increased by more than five months, in patients treated with Erbitux + FOLFIRI compared with FOLFIRI alone, whose cancer had spread beyond the liver (non-LLD)- Rates of potentially curative liver surgery increased 2-3 fold in patients treated by Erbitux in combination with either FOLFIRI or FOLFOX, compared to either alone, in patients whose cancer had spread only to their liver (LLD), although these did not reach statistical significance These new overall survival data support the previous finding from the CRYSTAL study2,3, in which a significant survival benefit of 3. | 06 June 2011 |
| Second Phase 3 Study Of YERVOY™ (ipilimumab) In Metastatic Melanoma Meets Primary Endpoint Of Overall Survival Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. | 06 June 2011 |
| Sanofi's Investigational Semuloparin In Cancer Patients Initiating Chemotherapy Shows A 64% Risk Reduction In Life-Threatening Venous Thrombo-Embolism Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%[i], meeting the study primary endpoint (respectively 1. | 06 June 2011 |
| ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL). | 06 June 2011 |
| Synta Announces Ganetespib Phase 2 Non-Small Cell Lung Cancer Trial Results Show Encouraging Single Agent Clinical Activity Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease. | 06 June 2011 |
| Genentech Announces Data To Show Avastin-Based Regimen Halved The Risk Of Disease Getting Worse In Women With Recurrent Ovarian Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. | 06 June 2011 |
| Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit For Myelofibrosis Patients In Two Phase III Studies At ASCO Annual Meeting Incyte Corporation (Nasdaq:INCY) announced today results from the global, pivotal Phase III clinical program of ruxolitinib (INCB18424 or INC424) in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. | 06 June 2011 |
| Alnylam Presents Phase I Data For ALN-VSP, An RNAi Therapeutic For The Treatment Of Liver Cancers, At ASCO Meeting Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. | 06 June 2011 |
| Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity In Patients With Metastatic Ovarian Cancer Exelixis, Inc. (NASDAQ:EXEL) reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. | 06 June 2011 |
| Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer TRION Pharma GmbH announces today that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. | 06 June 2011 |
| Studies Focus On Cancer As A Chronic Disease New research results focusing on cancer as a chronic disease were released today at a press briefing at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). "We are increasingly translating our growing understanding of cancer biology into longer lives for people with cancer" said news briefing moderator Mark G. | 06 June 2011 |
| Studies Report Results Defining New Standards Of Clinical Cancer Care Studies describing progress in establishing new treatment standards against advanced cancers, specifically melanoma and neuroblastoma, were released today at a press briefing at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Practice-Changing Cancer Trial Shows Additional Radiation Decreases Cancer Recurrence, Canada A Canadian-led clinical trial has found that additional radiation treatment improves disease-free survival in women with early breast cancer and reduces the risk of cancer recurrence, a finding that could change the standard treatment for this group of patients. | 06 June 2011 |
| Landmark Breast Cancer Prevention Trial Finds Exemestane Significantly Reduces Risk Of Breast Cancer, Canada A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo. | 06 June 2011 |
| Hormone Test Predicts Ovarian Function After Chemotherapy For Breast Cancer A test that shows how many eggs a woman has in her ovaries may help young women with breast cancer know what their reproductive function will be after chemotherapy, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Targeted Cancer Therapy Kills Prostate Tumor Cells A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Alpharadin Significantly Improves Overall Survival In Phase III In Patients With Castration-Resistant Prostate Cancer That Has Spread To The Bone Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival. | 06 June 2011 |
| Ovarian Cancer Screening Does Not Cut Disease-Related Mortality New data demonstrates that average-risk women who are screened for ovarian cancer using serum cancer antigen 125 (CA-125) and transvaginal ultrasound do not have a lower ovarian cancer mortality rate than women who receive usual care. | 06 June 2011 |
| Biopsy Needle Provides Advanced Accuracy In Diagnosing Cancers Of GI Tract Results from a multicenter European study[1] suggest that a new, large-core biopsy needle designed for use with an endoscopic ultrasound (EUS) scope may help to overcome limitations of current EUS methods for biopsies of lesions in the gastrointestinal (GI) tract and surrounding tissue. | 06 June 2011 |
| Veterans Health Administration (VHA) At Least As Good As Private Sector For Cancer Care VHA (Veterans Health Administration) services were found to be either similar or better than the private sector for several chronic disease treatments, including cancer, researchers reported in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Cardiovascular / Cardiology News | |
| PARTNER Shows Similar One-Year Survival For Catheter-Based AVR And Open AVR In High-Risk Patients Less invasive catheter-based aortic valve replacement and open valve-replacement surgery have a similar one-year survival for patients at high risk for surgery.Results from The PARTNER (Placement of AoRTic traNscathetER valves) Trial - the world's first randomized clinical trial of a transcatheter aortic heart valve - were published today in the New England Journal of Medicine. | 06 June 2011 |
| Smoking Raises Peripheral Artery Disease Risk 10-Fold In Women Regular smoking raises a female's risk of developing PAD (peripheral artery disease) 10-fold, researchers from Harvard Medical School revealed in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Clinical Trials / Drug Trials News | |
| Landmark Breast Cancer Prevention Trial Finds Exemestane Significantly Reduces Risk Of Breast Cancer, Canada A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo. | 06 June 2011 |
| Colorectal Cancer News | |
| Novartis' Gleevec Cancer "Magic Bullet" Extends Life In GIST Patients Stomach cancer and gastronintestinal stromal tumors (GIST) can be an expensive disease to treat, but for approximately $5,000 a month Novartis AG's cancer pill Gleevec (imatinib) seems to extend the lives of patients with this type of gastrointestinal cancer over the long-term when taking the drug for three years after surgery. | 06 June 2011 |
| ZALTRAP™ (Aflibercept) Significantly Improved Survival In Previously Treated Metastatic Colorectal Cancer Patients Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011. | 06 June 2011 |
| Symphogen Presents Results From The First Clinical Trial With Sym004 At ASCO Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004. Based on the data, the poster authors concluded that Sym004 is well tolerated, and shows preliminary signs of clinical effect. | 06 June 2011 |
| Dermatology News | |
| Advanced Skin Cancer Hope With Vemurafenib And Ipilimumab Patients with advanced melanoma may live longer with Ipilimumab, and have a better likelihood of surviving longer on Vemurafenib than chemotherapy, scientists revealed in the Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Second Phase 3 Study Of YERVOY™ (ipilimumab) In Metastatic Melanoma Meets Primary Endpoint Of Overall Survival Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. | 06 June 2011 |
| Diabetes News | |
| Women's Risk Of Heart Disease After Gestational Diabetes Differs By Race New research finds that gestational diabetes, or pregnancy-related diabetes, may not raise the risk of heart disease independent of other cardiovascular risk factors except in certain high-risk populations, such as Hispanics. | 06 June 2011 |
| One In Five People With Diabetes Miss Up To 15 Working Hours Per Month Due To Low Blood Sugar Nearly one in five people with diabetes are regularly unable to attend a full day at work due to disruption caused by episodes of dangerously low blood sugar, known as a hypoglycaemic event.1 A new survey, focusing on productivity loss following hypoglycaemic events, was published today in the journal Value in Health. | 06 June 2011 |
| Study Finds Treatment With Metreleptin Improved Diabetes And Lipid Control In Patients With Partial Lipodystrophy Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. | 06 June 2011 |
| Ear, Nose and Throat News | |
| Sunovion Announces FDA Acceptance Of New Drug Application For Ciclesonide HFA Nasal Aerosol Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation has been accepted by the U. | 06 June 2011 |
| Endocrinology News | |
| Low Vitamin D Levels Are Related To Decreased Response To Osteoporosis Medicine Women with low bone density are seven times more likely to benefit from a bisphosphonate drug when their vitamin D blood levels are above recent recommendations from the Institute of Medicine (IOM) as adequate for bone health. | 06 June 2011 |
| Intravenous Nutrition In Critically Ill Patients Should Be Delayed, Study Finds Patients in the intensive care unit who do not tolerate adequate nutrition from tube feeding should wait a week before receiving intravenous (IV) feeding because, compared with early IV feeding, it enhances recovery from critical illness. | 06 June 2011 |
| Testosterone Therapy Improves Memory In Postmenopausal Women Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Yearly Zoledronic Acid At Lower-than-Standard Doses Increases Bone Density A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. | 06 June 2011 |
| Study Finds Treatment With Metreleptin Improved Diabetes And Lipid Control In Patients With Partial Lipodystrophy Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. | 06 June 2011 |
| Elderly May Be More Likely To Die If They Have Subclinical Hyperthyroidism A common hormone abnormality in older adults-a mild form of overactive thyroid called subclinical hyperthyroidism-is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Cut Down On "Carbs" To Reduce Body Fat, Study Authors Say A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Eye Health / Blindness News | |
| Helping Children Succeed - EyeMed Vision Care Introduces EyeMed KidsEyes Vision Benefit EyeMed Vision Care, one of the nation's leading vision benefits companies and part of Luxottica (NYSE: LUX), a leader in vision care and eyewear, introduces a first-to-market vision benefit that is tailored to meet the unique needs of children 18 years and younger and supports their active lifestyle. | 06 June 2011 |
| Lucentis(R) (Ranibizumab) Launched In The UK For The Treatment Of Vision Loss Due To Macular Oedema Secondary To Retinal Vein Occlusion (RVO) Novartis Pharmaceuticals UK Ltd today announced that Lucentis® (ranibizumab) has launched in the UK for the treatment of visual impairment due to macular oedema secondary to Retinal Vein Occlusion (RVO). | 06 June 2011 |
| Fertility News | |
| Hormone Test Predicts Ovarian Function After Chemotherapy For Breast Cancer A test that shows how many eggs a woman has in her ovaries may help young women with breast cancer know what their reproductive function will be after chemotherapy, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| GastroIntestinal / Gastroenterology News | |
| Novartis' Gleevec Cancer "Magic Bullet" Extends Life In GIST Patients Stomach cancer and gastronintestinal stromal tumors (GIST) can be an expensive disease to treat, but for approximately $5,000 a month Novartis AG's cancer pill Gleevec (imatinib) seems to extend the lives of patients with this type of gastrointestinal cancer over the long-term when taking the drug for three years after surgery. | 06 June 2011 |
| ZALTRAP™ (Aflibercept) Significantly Improved Survival In Previously Treated Metastatic Colorectal Cancer Patients Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011. | 06 June 2011 |
| ASCO 2011: New Analysis Further Reinforces Erbitux Benefits For Patients With Metastatic Bowel Cancer At the start of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Merck Serono, a division of Merck KGaA, Darmstadt, Germany, presented a retrospective analysis of the CRYSTAL and OPUS trials which demonstrated that, by treating a specific population of metastatic bowel cancer patients (KRAS wild-type) with Erbitux® (cetuximab) in combination with standard chemotherapy1: - Overall survival was significantly increased by more than five months, in patients treated with Erbitux + FOLFIRI compared with FOLFIRI alone, whose cancer had spread beyond the liver (non-LLD)- Rates of potentially curative liver surgery increased 2-3 fold in patients treated by Erbitux in combination with either FOLFIRI or FOLFOX, compared to either alone, in patients whose cancer had spread only to their liver (LLD), although these did not reach statistical significance These new overall survival data support the previous finding from the CRYSTAL study2,3, in which a significant survival benefit of 3. | 06 June 2011 |
| Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer TRION Pharma GmbH announces today that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. | 06 June 2011 |
| Biopsy Needle Provides Advanced Accuracy In Diagnosing Cancers Of GI Tract Results from a multicenter European study[1] suggest that a new, large-core biopsy needle designed for use with an endoscopic ultrasound (EUS) scope may help to overcome limitations of current EUS methods for biopsies of lesions in the gastrointestinal (GI) tract and surrounding tissue. | 06 June 2011 |
| Genetics News | |
| Expert Calls At-Home Sport Genetic Testing Into Question An emerging trend in youth sports gives some experts cause for concern, according to a session being presented today at the American College of Sports Medicine's (ACSM) 58th Annual Meeting and 2nd World Congress on Exercise is Medicine®. | 06 June 2011 |
| Heart Disease News | |
| Women's Risk Of Heart Disease After Gestational Diabetes Differs By Race New research finds that gestational diabetes, or pregnancy-related diabetes, may not raise the risk of heart disease independent of other cardiovascular risk factors except in certain high-risk populations, such as Hispanics. | 06 June 2011 |
| HIV / AIDS News | |
| UAB On The Front Lines In 30-Year War On HIV/AIDS In a span of three decades a disease appeared, created a public health crisis and killed millions worldwide before modern medicine commuted a certain death sentence into a chronic, manageable disease. | 06 June 2011 |
| HIV Treatment Reaching 6.6 Million People, But Majority Still In Need An estimated 6.6 million people in low- and middle-income countries were receiving antiretroviral therapy (ART) for HIV/AIDS at the end of 2010, according to the WHO. Of this, an estimated 420 000-460 000 were children. | 06 June 2011 |
| Immune System / Vaccines News | |
| Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer TRION Pharma GmbH announces today that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. | 06 June 2011 |
| Anti-Obesity Vaccine Reduces Food Consumption In Animals A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Infectious Diseases / Bacteria / Viruses News | |
| Finding Source Of E. Coli Outbreak In Germany - Why Has It Taken So Long? Dr. Mark Fielder, from Kingston University, London, has been keeping a close watch on how the European E. Coli outbreak has developed. Below, he answers some key question about the situation. | 06 June 2011 |
| Big Pharma Follows Gates' Lead; Slashes Rota Vaccine Prices For Poor Last month in Geneva, Bill Gates laid out his vision for the impact that broadening access to vaccines can have on the world. Now, only a few weeks after his inspirational speech, GlaxoSmithKline (GSK) has promised to cut a whopping 95% off its rotavirus vaccine for sale to the globe's poorest countries, while Merck has also said it would cut the price on its vaccine against the same illness. | 06 June 2011 |
| Initial: 'Dirty Hands' - Only One In Three Brits Wash Their Hands After Each Visit To The Toilet With E.coli once again in the headlines, research by global hygiene experts, Initial, shows that only one in three Brits wash their hands after a visit to the toilet. As E.coli bacteria can spread from person to person by what is known as the 'faecal-oral' route, the transference possibilities of bacteria are immense. | 06 June 2011 |
| FDA Statement On E. Coli O104 Outbreak In Europe The U.S. FDA has been in routine contact with the European Union and the U.S. Centers for Disease Control and Prevention to monitor the current outbreak of E. coli O104 and to track any illnesses in the U. | 06 June 2011 |
| Liver Disease / Hepatitis News | |
| Alnylam Presents Phase I Data For ALN-VSP, An RNAi Therapeutic For The Treatment Of Liver Cancers, At ASCO Meeting Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. | 06 June 2011 |
| Lung Cancer News | |
| NewYork-Presbyterian/Weill Cornell Research Presented At American Society Of Clinical Oncologists Meeting Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The meeting takes place June 3-7, at McCormick Place, Chicago. | 06 June 2011 |
| Synta Announces Ganetespib Phase 2 Non-Small Cell Lung Cancer Trial Results Show Encouraging Single Agent Clinical Activity Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease. | 06 June 2011 |
| Lymphoma / Leukemia / Myeloma News | |
| ImmunoGen, Inc. Announces Positive Clinical Data Presented On IMGN901 In The Treatment Of Multiple Myeloma ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation (abstract #8013) at the ASCO 2011 Annual Meeting in Chicago. | 06 June 2011 |
| Survival Niche For Cancer Cells Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors. | 06 June 2011 |
| ARIAD Announces Initial Clinical Data On Ponatinib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML). In addition to being an investigational pan-BCR-ABL inhibitor for use in chronic myeloid leukemia (CML), ponatinib selectively and potently inhibits certain other tyrosine kinases, including a specific mutation of FLT3 called the internal tandem duplication (ITD). | 06 June 2011 |
| ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL). | 06 June 2011 |
| Medical Devices / Diagnostics News | |
| Mazor Robotics Launches Renaissance™, The Next Generation Of Its Highly Accurate Robotic Surgical Guidance Systems Mazor Robotics Ltd. (TASE: MZOR), the leader in innovative surgical robots and complementary products for spine surgery, introduced today Renaissance™, the next-generation of the world's only spinal robotic surgical guidance system. | 06 June 2011 |
| Medicare / Medicaid / SCHIP News | |
| New Affordable Care Act Support To Improve Care Coordination For Nearly 200,000 People With Medicare Today, the Department of Health and Human Services (HHS) announced the Federally Qualified Health Center Advanced Primary Care Practice (FQHC APCP) demonstration project, a new Affordable Care Act initiative that will pay an estimated $42 million over three years to up to 500 FQHCs to coordinate care for Medicare patients. | 06 June 2011 |
| Veterans Health Administration (VHA) At Least As Good As Private Sector For Cancer Care VHA (Veterans Health Administration) services were found to be either similar or better than the private sector for several chronic disease treatments, including cancer, researchers reported in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Melanoma / Skin Cancer News | |
| Clinical Trial At The Cancer Institute Of New Jersey Studies Combination Of ALS And Kidney Cancer Drugs For Melanoma Use Could a drug that is now used to treat a nerve cell condition and another prescribed to treat kidney cancer be combined to combat the deadliest form of skin cancer? That is the focus of research now underway at The Cancer Institute of New Jersey (CINJ), which aims to determine safe dosing levels for the drugs known as riluzole and sorafenib when used together in the treatment of patients with melanoma. | 06 June 2011 |
| Advanced Skin Cancer Hope With Vemurafenib And Ipilimumab Patients with advanced melanoma may live longer with Ipilimumab, and have a better likelihood of surviving longer on Vemurafenib than chemotherapy, scientists revealed in the Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Second Phase 3 Study Of YERVOY™ (ipilimumab) In Metastatic Melanoma Meets Primary Endpoint Of Overall Survival Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. | 06 June 2011 |
| Studies Report Results Defining New Standards Of Clinical Cancer Care Studies describing progress in establishing new treatment standards against advanced cancers, specifically melanoma and neuroblastoma, were released today at a press briefing at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Combination Antibody Therapy Shows Promise In Metastatic Melanoma A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators. | 06 June 2011 |
| Menopause News | |
| Testosterone Therapy Improves Memory In Postmenopausal Women Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Flaxseed No Cure For Hot Flashes During Breast Cancer Or Menopause Flaxseed provides no benefit in easing hot flashes among breast cancer patients and postmenopausal women, according to a Mayo Clinic and North Central Cancer Treatment Group (NCCTG) study. The randomized, placebo-controlled study was conducted on 188 women between October and December 2009 and found no statistically significant difference in mean hot flash scores between women taking flaxseed and those taking a placebo. | 06 June 2011 |
| Mental Health News | |
| Huge Global Burden Of Neuropsychiatric Disorders among 10 To 24 Year-Olds Unipolar depression, schizophrenia, bipolar disorder and alcohol use are among the neuropsychiatric disorders that represent 45% of the disease burden among teenagers and young adults worldwide. | 06 June 2011 |
| CBT Helps Depressive Symptoms For Patients In Residential Substance Abuse Treatment Programs CBT (cognitive behavioral therapy) appears to help patients in drug and alcohol abuse treatment programs with symptoms of depression, researchers from the RAND Corporation, Santa Monica, California reported in Archives of General Psychiatry today. | 06 June 2011 |
| Brain Gray Matter Volume Different In Males With Violent Behavior History Brain scans have revealed that males with a history of violent behavior have more gray matter in certain parts of the brain, while those with a substance abuse disorder have less, researchers from the University of Duisburg-Essen, Germany, revealed in Archives of General Psychiatry. | 06 June 2011 |
| MRI / PET / Ultrasound News | |
| GE Healthcare Advances Innovative Technologies To Help Clinicians Provide Better Health For More People Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio. | 06 June 2011 |
| Multiple Sclerosis News | |
| Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of Multiple Sclerosis Centers Biogen Idec (NASDAQ: BIIB) today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX®(interferon beta-1a) dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy. | 06 June 2011 |
| Muscular Dystrophy / ALS News | |
| Muscle Development: A Dance Of Cellular Skeletons Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell's territory, eventually forcing the cells to combine. | 06 June 2011 |
| Neurology / Neuroscience News | |
| Mazor Robotics Launches Renaissance™, The Next Generation Of Its Highly Accurate Robotic Surgical Guidance Systems Mazor Robotics Ltd. (TASE: MZOR), the leader in innovative surgical robots and complementary products for spine surgery, introduced today Renaissance™, the next-generation of the world's only spinal robotic surgical guidance system. | 06 June 2011 |
| New Approaches Open Up In Spinal Muscular Atrophy Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences (Early Edition, week of June 6), researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies. | 06 June 2011 |
| Mild cognitive impairment may be linked to functional impairment among older patients The majority of older individuals with mild cognitive impairment also have problems with at least one type of function, researchers from the New York State Psychiatric Institute reported in Archives of General Psychiatry. | 06 June 2011 |
| Brain Gray Matter Volume Different In Males With Violent Behavior History Brain scans have revealed that males with a history of violent behavior have more gray matter in certain parts of the brain, while those with a substance abuse disorder have less, researchers from the University of Duisburg-Essen, Germany, revealed in Archives of General Psychiatry. | 06 June 2011 |
| Nursing / Midwifery News | |
| University Of Chicago RNs Approve New Contract, Praise 'Safer Staffing,' 'Improved Respect' University of Chicago Medical Center registered nurses have voted overwhelmingly to approve a new collective bargaining contract with the University, National Nurses United said today. The RNs voted Wednesday and Thursday on the new agreement that they say achieves the nurses' main negotiating goals with major improvements in patient care protections and economic and workplace standards for the RNs, as well as rejecting all of the hospital's concessionary demands. | 06 June 2011 |
| Nutrition / Diet News | |
| Finding Source Of E. Coli Outbreak In Germany - Why Has It Taken So Long? Dr. Mark Fielder, from Kingston University, London, has been keeping a close watch on how the European E. Coli outbreak has developed. Below, he answers some key question about the situation. | 06 June 2011 |
| Intravenous Nutrition In Critically Ill Patients Should Be Delayed, Study Finds Patients in the intensive care unit who do not tolerate adequate nutrition from tube feeding should wait a week before receiving intravenous (IV) feeding because, compared with early IV feeding, it enhances recovery from critical illness. | 06 June 2011 |
| Cut Down On "Carbs" To Reduce Body Fat, Study Authors Say A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Adherence To Certain Dietary Pattern Associated With Lower BMI In Adolescent Girls Adolescent girls whose diet resembles one recommended for adults with hypertension appear to have smaller gains in overall body mass index (BMI) over 10 years, according to a report in the June issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. | 06 June 2011 |
| Obesity / Weight Loss / Fitness News | |
| Modern Dancers Exhibit Favorable Fat Distribution Participating in regular physical activity, such as modern dance, may help young adults achieve a healthier distribution of body fat, according to research being presented today at the 58th Annual Meeting of the American College of Sports Medicine and 2nd World Congress on Exercise is Medicine®. | 06 June 2011 |
| Pregnant Women Can Prevent Excess Weight Gain With Simple Steps A new study reports that a low-cost healthy lifestyle program, including self-weighing weekly or monthly, by pregnant women with pre-existing overweight can prevent them from gaining too much weight during early pregnancy. | 06 June 2011 |
| Anti-Obesity Vaccine Reduces Food Consumption In Animals A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Calorie-Burning Brown Fat Is A Potential Obesity Treatment A new study suggests that many adults have large amounts of brown fat, the "good" fat that burns calories to keep us warm, and that it may be possible to make even more of this tissue.The study's lead author, Aaron Cypess, MD, PhD, will present the results Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Weight Loss After Gastric Bypass Surgery Reduces Expression Of Alzheimer's Genes Obesity is a risk factor for Alzheimer's disease, but weight loss due to bariatric surgery may reduce the risk of this common dementia, a new study suggests. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Cut Down On "Carbs" To Reduce Body Fat, Study Authors Say A modest reduction in consumption of carbohydrate foods may promote loss of deep belly fat, even with little or no change in weight, a new study finds. Presentation of the study results will be Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Adherence To Certain Dietary Pattern Associated With Lower BMI In Adolescent Girls Adolescent girls whose diet resembles one recommended for adults with hypertension appear to have smaller gains in overall body mass index (BMI) over 10 years, according to a report in the June issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. | 06 June 2011 |
| Ovarian Cancer News | |
| Roche's Pricy Avastin May Slow Ovarian Cancer Progression Roche's blockbuster cancer drug Avastin has now additionally been shown to slow the progression of ovarian cancer but does not extend life necessarily according to information presented at this week's American Society of Clinical Oncology annual meeting. | 06 June 2011 |
| Screenings Appear Not To Reduce Risk Of Ovarian Cancer Death A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems. | 06 June 2011 |
| Landmark UK-Led Trial Shows Avastin(R) (Bevacizumab) Can Prolong Life In Women With Advanced Ovarian Cancer Data presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago show, for the first time, that Avastin (bevacizumab) improves overall survival (OS) in women with advanced ovarian cancer2,3 - the deadliest gynaecological cancer in the UK1 - offering hope of a treatment breakthrough for thousands of women diagnosed with the disease each year. | 06 June 2011 |
| Genentech Announces Data To Show Avastin-Based Regimen Halved The Risk Of Disease Getting Worse In Women With Recurrent Ovarian Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. | 06 June 2011 |
| Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity In Patients With Metastatic Ovarian Cancer Exelixis, Inc. (NASDAQ:EXEL) reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. | 06 June 2011 |
| Ovarian Cancer Screening Does Not Cut Disease-Related Mortality New data demonstrates that average-risk women who are screened for ovarian cancer using serum cancer antigen 125 (CA-125) and transvaginal ultrasound do not have a lower ovarian cancer mortality rate than women who receive usual care. | 06 June 2011 |
| Pain / Anesthetics News | |
| Women's Advocates Send Letter To Congressional Leaders Requesting A Hearing On Chronic Pain The Campaign to End Chronic Pain in Women, led by organizational leaders from the CFIDS Association of America, Endometriosis Association, National Vulvodynia Association, and The TMJ Association, called on congressional leaders to convene a hearing on our nation's chronic pain epidemic and examine solutions that could relieve suffering and substantially reduce health care costs. | 06 June 2011 |
| Indiana University Neuroscientists Map A New Target To Wipe Pain Away Researchers at the Indiana University School of Medicine have discovered a peptide that short circuits a pathway for chronic pain. Unlike current treatments this peptide does not exhibit deleterious side effects such as reduced motor coordination, memory loss or depression, according to an article in Nature Medicine posted online June 5, 2011. | 06 June 2011 |
| Early Results Of Development Program In Nano-Formulated NSAIDs Show Potential For Faster Pain Relief At Lower Doses A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society (AHS). | 06 June 2011 |
| Pediatrics / Children's Health News | |
| UNICEF Executive Director Calls On Reaching The Poorest, The Most Disadvantaged, To Meet MDG Goals For Children UNICEF Executive Director Anthony Lake today joined world leaders at a meeting hosted by the Government of Japan to discuss how focusing investment on the most vulnerable can improve human security and accelerate global progress toward meeting the Millennium Development Goals. | 06 June 2011 |
| Studies Report Results Defining New Standards Of Clinical Cancer Care Studies describing progress in establishing new treatment standards against advanced cancers, specifically melanoma and neuroblastoma, were released today at a press briefing at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). | 06 June 2011 |
| Huge Global Burden Of Neuropsychiatric Disorders among 10 To 24 Year-Olds Unipolar depression, schizophrenia, bipolar disorder and alcohol use are among the neuropsychiatric disorders that represent 45% of the disease burden among teenagers and young adults worldwide. | 06 June 2011 |
| New Approaches Open Up In Spinal Muscular Atrophy Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences (Early Edition, week of June 6), researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies. | 06 June 2011 |
| Adherence To Certain Dietary Pattern Associated With Lower BMI In Adolescent Girls Adolescent girls whose diet resembles one recommended for adults with hypertension appear to have smaller gains in overall body mass index (BMI) over 10 years, according to a report in the June issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. | 06 June 2011 |
| Adult Partner Violence Linked To Childhood Bullying Males who bullied other children during their childhood are much more likely to be violent towards their intimates partners later on in life, researchers from the Harvard School of Public Health, Boston, reported in Archives of Pediatrics & Adolescent Medicine today. | 06 June 2011 |
| Pharma Industry / Biotech Industry News | |
| Big Pharma Follows Gates' Lead; Slashes Rota Vaccine Prices For Poor Last month in Geneva, Bill Gates laid out his vision for the impact that broadening access to vaccines can have on the world. Now, only a few weeks after his inspirational speech, GlaxoSmithKline (GSK) has promised to cut a whopping 95% off its rotavirus vaccine for sale to the globe's poorest countries, while Merck has also said it would cut the price on its vaccine against the same illness. | 06 June 2011 |
| Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of Multiple Sclerosis Centers Biogen Idec (NASDAQ: BIIB) today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX®(interferon beta-1a) dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy. | 06 June 2011 |
| Early Results Of Development Program In Nano-Formulated NSAIDs Show Potential For Faster Pain Relief At Lower Doses A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society (AHS). | 06 June 2011 |
| Pharmacy / Pharmacist News | |
| Early Results Of Development Program In Nano-Formulated NSAIDs Show Potential For Faster Pain Relief At Lower Doses A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society (AHS). | 06 June 2011 |
| Pregnancy / Obstetrics News | |
| Women's Risk Of Heart Disease After Gestational Diabetes Differs By Race New research finds that gestational diabetes, or pregnancy-related diabetes, may not raise the risk of heart disease independent of other cardiovascular risk factors except in certain high-risk populations, such as Hispanics. | 06 June 2011 |
| Pregnant Women Can Prevent Excess Weight Gain With Simple Steps A new study reports that a low-cost healthy lifestyle program, including self-weighing weekly or monthly, by pregnant women with pre-existing overweight can prevent them from gaining too much weight during early pregnancy. | 06 June 2011 |
| Preventive Medicine News | |
| National Institute Of Health And Clinical Excellence Outlines Guidelines For Preventing Delirium In The Clinical Setting Delirium is a common disorder characterized by a recent onset of symptoms related to impaired cognitive function. In addition to causing stress to patients and families, delirium increases health care costs due to longer hospital stays and the need for long-term care. | 06 June 2011 |
| Prostate / Prostate Cancer News | |
| Pre-Clinical Studies Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes. | 06 June 2011 |
| NewYork-Presbyterian/Weill Cornell Research Presented At American Society Of Clinical Oncologists Meeting Among those presenting at this year's American Society of Clinical Oncologists meeting are physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The meeting takes place June 3-7, at McCormick Place, Chicago. | 06 June 2011 |
| Targeted Cancer Therapy Kills Prostate Tumor Cells A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Alpharadin Significantly Improves Overall Survival In Phase III In Patients With Castration-Resistant Prostate Cancer That Has Spread To The Bone Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival. | 06 June 2011 |
| Psychology / Psychiatry News | |
| Gay Teens At Much Higher Risk For Unhealthy Behavior; Suicide, Drugs Teens can be troubled, but a huge new study released this week by the U.S. Centers for Disease Control and Prevention (CDC) reports that gay, lesbian or bisexual adolescents are more likely than their heterosexual peers to take unhealthy risks. | 06 June 2011 |
| As People Age Their Moral Responses Change Moral responses change as people age says a new study from the University of Chicago.Both preschool children and adults distinguish between damage done either intentionally or accidently when assessing whether a perpetrator has done something wrong, said study author Jean Decety. | 06 June 2011 |
| Huge Global Burden Of Neuropsychiatric Disorders among 10 To 24 Year-Olds Unipolar depression, schizophrenia, bipolar disorder and alcohol use are among the neuropsychiatric disorders that represent 45% of the disease burden among teenagers and young adults worldwide. | 06 June 2011 |
| CBT Helps Depressive Symptoms For Patients In Residential Substance Abuse Treatment Programs CBT (cognitive behavioral therapy) appears to help patients in drug and alcohol abuse treatment programs with symptoms of depression, researchers from the RAND Corporation, Santa Monica, California reported in Archives of General Psychiatry today. | 06 June 2011 |
| Brain Gray Matter Volume Different In Males With Violent Behavior History Brain scans have revealed that males with a history of violent behavior have more gray matter in certain parts of the brain, while those with a substance abuse disorder have less, researchers from the University of Duisburg-Essen, Germany, revealed in Archives of General Psychiatry. | 06 June 2011 |
| Adult Partner Violence Linked To Childhood Bullying Males who bullied other children during their childhood are much more likely to be violent towards their intimates partners later on in life, researchers from the Harvard School of Public Health, Boston, reported in Archives of Pediatrics & Adolescent Medicine today. | 06 June 2011 |
| Public Health News | |
| Gay Teens At Much Higher Risk For Unhealthy Behavior; Suicide, Drugs Teens can be troubled, but a huge new study released this week by the U.S. Centers for Disease Control and Prevention (CDC) reports that gay, lesbian or bisexual adolescents are more likely than their heterosexual peers to take unhealthy risks. | 06 June 2011 |
| CDC Report Finds Gay, Lesbian And Bisexual Students At Greater Risk For Unhealthy, Unsafe Behaviors Students who report being gay, lesbian or bisexual and students who report having sexual contact only with persons of the same sex or both sexes are more likely than heterosexual students and students who report having sexual contact only with the opposite sex to engage in unhealthy risk behaviors such as tobacco use, alcohol and other drug use, sexual risk behaviors, suicidal behaviors, and violence, according to a study by the Centers for Disease Control and Prevention. | 06 June 2011 |
| Greater Clarity Needed For Doctors On Prescribing For Friends And Family, UK MPS welcomes the GMC's review of its prescribing guidance, Good practice in prescribing and managing medicines and devices but believes greater clarity is needed so that doctors know what is appropriate when it comes to prescribing for themselves and those close to them. | 06 June 2011 |
| FDA Statement On E. Coli O104 Outbreak In Europe The U.S. FDA has been in routine contact with the European Union and the U.S. Centers for Disease Control and Prevention to monitor the current outbreak of E. coli O104 and to track any illnesses in the U. | 06 June 2011 |
| Take Extra Precautions To Prevent Heat Illnesses The combination of record-breaking heat and humidity presently affecting Alabama can be deadly. Now that the National Weather Service has informed the public about high heat index values, the Alabama Department of Public Health advises citizens to be alert to the warning signals of heat illnesses. | 06 June 2011 |
| Radiology / Nuclear Medicine News | |
| GE Healthcare Advances Innovative Technologies To Help Clinicians Provide Better Health For More People Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio. | 06 June 2011 |
| Practice-Changing Cancer Trial Shows Additional Radiation Decreases Cancer Recurrence, Canada A Canadian-led clinical trial has found that additional radiation treatment improves disease-free survival in women with early breast cancer and reduces the risk of cancer recurrence, a finding that could change the standard treatment for this group of patients. | 06 June 2011 |
| Ovarian Cancer Screening Does Not Cut Disease-Related Mortality New data demonstrates that average-risk women who are screened for ovarian cancer using serum cancer antigen 125 (CA-125) and transvaginal ultrasound do not have a lower ovarian cancer mortality rate than women who receive usual care. | 06 June 2011 |
| Regulatory Affairs / Drug Approvals News | |
| Sunovion Announces FDA Acceptance Of New Drug Application For Ciclesonide HFA Nasal Aerosol Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation has been accepted by the U. | 06 June 2011 |
| BioTime Receives NIH Approval For Two GMP Human Embryonic Stem Cell Lines BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human embryonic stem (hES) cell lines, ESI-014 and ESI-017, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. | 06 June 2011 |
| Seniors / Aging News | |
| Elderly May Be More Likely To Die If They Have Subclinical Hyperthyroidism A common hormone abnormality in older adults-a mild form of overactive thyroid called subclinical hyperthyroidism-is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Muscle Development: A Dance Of Cellular Skeletons Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell's territory, eventually forcing the cells to combine. | 06 June 2011 |
| Mild cognitive impairment may be linked to functional impairment among older patients The majority of older individuals with mild cognitive impairment also have problems with at least one type of function, researchers from the New York State Psychiatric Institute reported in Archives of General Psychiatry. | 06 June 2011 |
| Sleep / Sleep Disorders / Insomnia News | |
| For Best Sleep, Work Up A Sweat In The Morning Should I exercise in the morning or the evening? New research on physical activity and sleep architecture being presented today at the 58th Annual Meeting of the American College of Sports Medicine and the 2nd World Congress on Exercise is Medicine® may finally answer that age-old question. | 06 June 2011 |
| Smoking / Quit Smoking News | |
| Smoking Raises Peripheral Artery Disease Risk 10-Fold In Women Regular smoking raises a female's risk of developing PAD (peripheral artery disease) 10-fold, researchers from Harvard Medical School revealed in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Sports Medicine / Fitness News | |
| Great Britain Team Doctors To Undertake Pioneering Study At European Maccabi Games Dr Robert Fearn, a gastroenterologist at Barnet General Hospital, and Dr Marc Wittenberg, an anaesthetist at the Royal Free Hospital in London, the two doctors leading the medical team of this year's Great Britain squad at the 13th European Maccabi Games in Vienna, Austria, from 05 to 13 July, will be undertaking a pioneering sports nutrition study designed to examine the effect of nitrates on the fitness levels of athletes. | 06 June 2011 |
| Modern Dancers Exhibit Favorable Fat Distribution Participating in regular physical activity, such as modern dance, may help young adults achieve a healthier distribution of body fat, according to research being presented today at the 58th Annual Meeting of the American College of Sports Medicine and 2nd World Congress on Exercise is Medicine®. | 06 June 2011 |
| For Best Sleep, Work Up A Sweat In The Morning Should I exercise in the morning or the evening? New research on physical activity and sleep architecture being presented today at the 58th Annual Meeting of the American College of Sports Medicine and the 2nd World Congress on Exercise is Medicine® may finally answer that age-old question. | 06 June 2011 |
| Expert Calls At-Home Sport Genetic Testing Into Question An emerging trend in youth sports gives some experts cause for concern, according to a session being presented today at the American College of Sports Medicine's (ACSM) 58th Annual Meeting and 2nd World Congress on Exercise is Medicine®. | 06 June 2011 |
| Geocaching Is Good Exercise For Tech-Savvy Teens Geocaching - a technology trend that has taken hold in more than 100 countries worldwide - may be more than just fun, according to research being presented today at the American College of Sports Medicine's 58th Annual Meeting and 2nd World Congress on Exercise is Medicine®. | 06 June 2011 |
| Athletic Girls More Likely To Have Impaired Bone Structure If Menstrual Cycle Stops Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. | 06 June 2011 |
| Stem Cell Research News | |
| BioTime Receives NIH Approval For Two GMP Human Embryonic Stem Cell Lines BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human embryonic stem (hES) cell lines, ESI-014 and ESI-017, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. | 06 June 2011 |
| Stem Cell Treatment May Become Option To Treat Nonhealing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. | 06 June 2011 |
| Stroke News | |
| ABCD2 Score To Identify People At Risk Of Stroke Has Limited Clinical Application The ABCD2 score used to identify people at risk of stroke after suffering a transient ischemic attack - a "mini" or "warning" stroke - is not sensitive enough to distinguish between high- and low-risk patients and has limited clinical application, states an article in CMAJ (Canadian Medical Association Journal). | 06 June 2011 |
| Urology / Nephrology News | |
| Impax Laboratories Confirms Patent Suit Relating To Generic Detrol(R) Immediate-Release 1 Mg And 2 Mg Tablets Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB (collectively, "Pfizer") have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol® (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets. | 06 June 2011 |
| Vascular News | |
| Carotid Artery Interventions For Cerebrovascular Disease Compared New data in the June 2011 issue of the Journal of Vascular Surgery®, the official publication of the Society for Vascular Surgery®, reveals that carotid endarterectomy (CEA) may be the preferred treatment for women who require intervention for cerebrovascular disease. | 06 June 2011 |
| Sanofi's Investigational Semuloparin In Cancer Patients Initiating Chemotherapy Shows A 64% Risk Reduction In Life-Threatening Venous Thrombo-Embolism Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%[i], meeting the study primary endpoint (respectively 1. | 06 June 2011 |
| PARTNER Shows Similar One-Year Survival For Catheter-Based AVR And Open AVR In High-Risk Patients Less invasive catheter-based aortic valve replacement and open valve-replacement surgery have a similar one-year survival for patients at high risk for surgery.Results from The PARTNER (Placement of AoRTic traNscathetER valves) Trial - the world's first randomized clinical trial of a transcatheter aortic heart valve - were published today in the New England Journal of Medicine. | 06 June 2011 |
| Smoking Raises Peripheral Artery Disease Risk 10-Fold In Women Regular smoking raises a female's risk of developing PAD (peripheral artery disease) 10-fold, researchers from Harvard Medical School revealed in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Veterans / Ex-Servicemen News | |
| Veterans Health Administration (VHA) At Least As Good As Private Sector For Cancer Care VHA (Veterans Health Administration) services were found to be either similar or better than the private sector for several chronic disease treatments, including cancer, researchers reported in the medical journal Annals of Internal Medicine. | 06 June 2011 |
| Women's Health / Gynecology News | |
| Screenings Appear Not To Reduce Risk Of Ovarian Cancer Death A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems. | 06 June 2011 |
| Women's Advocates Send Letter To Congressional Leaders Requesting A Hearing On Chronic Pain The Campaign to End Chronic Pain in Women, led by organizational leaders from the CFIDS Association of America, Endometriosis Association, National Vulvodynia Association, and The TMJ Association, called on congressional leaders to convene a hearing on our nation's chronic pain epidemic and examine solutions that could relieve suffering and substantially reduce health care costs. | 06 June 2011 |
| Ipsen Announces Discontinuation Of The Development Of Irosustat In Monotherapy Ipsen (Paris:IPN) (Euronext: IPN - ADR: IPSEY) today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decision is based on the futility analysis from the proof-of-concept trial phase II clinical study carried out in Europe in monotherapy in endometrial cancer, and on the phase I/II clinical study results obtained in metastatic prostate and breast cancers. | 06 June 2011 |
| Landmark UK-Led Trial Shows Avastin(R) (Bevacizumab) Can Prolong Life In Women With Advanced Ovarian Cancer Data presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago show, for the first time, that Avastin (bevacizumab) improves overall survival (OS) in women with advanced ovarian cancer2,3 - the deadliest gynaecological cancer in the UK1 - offering hope of a treatment breakthrough for thousands of women diagnosed with the disease each year. | 06 June 2011 |
| Testosterone Therapy Improves Memory In Postmenopausal Women Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston. | 06 June 2011 |
| Genentech Announces Data To Show Avastin-Based Regimen Halved The Risk Of Disease Getting Worse In Women With Recurrent Ovarian Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. | 06 June 2011 |
| Athletic Girls More Likely To Have Impaired Bone Structure If Menstrual Cycle Stops Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. | 06 June 2011 |
| You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
Tidak ada komentar:
Posting Komentar